Home  |  Contact

Cellosaurus OVMIU (CVCL_3112)

Cell line name OVMIU
Accession CVCL_3112
Resource Identification Initiative To cite this cell line use: OVMIU (RRID:CVCL_3112)
Comments Problematic cell line: Contaminated. Shown to be a OVSAYO derivative (PubMed=20143388). Originally thought to originate from a 46 year old female patient with an ovarian adenocarcinoma.
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00341.
Population: Japanese.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg249Met (c.746G>T); ClinVar=VCV000376653; Zygosity=Heterozygous (from parent cell line).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.26
Native American0.2
East Asian, North75.07
East Asian, South23.44
South Asian1.02
European, North0
European, South0
Disease High grade ovarian serous adenocarcinoma (NCIt: C105555)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_3115 (OVSAYO)
Sex of cell Female
Age at sampling 64Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB

Markers:
AmelogeninX
CSF1PO12
D5S81811,12
D7S82010,12
D13S3178,11
D16S5399,10
TH017
TPOX9,11
vWA17,18

Run an STR similarity search on this cell line
Web pages https://cellbank.nibiohn.go.jp/legacy/cellbank/qualitycontrol/identification/summary.htm
https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
Publications

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) JCRB; JCRB1049
JCRB; NIHS0302 - Discontinued
JCRB; NIHS0344 - Discontinued
Cell line databases/resources CLO; CLO_0037099
cancercelllines; CVCL_3112
Cell_Model_Passport; SIDM00465
Cosmic-CLP; 1240200
DepMap; ACH-002183
LINCS_LDP; LCL-1526
Biological sample resources BioSample; SAMN03151882
BioSample; SAMN03472489
CRISP screens repositories BioGRID_ORCS_Cell_line; 985
Chemistry resources GDSC; 1240200
PharmacoDB; OVMIU_1226_2019
Encyclopedic resources Wikidata; Q54937032
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM827252
GEO; GSM1670324
Polymorphism and mutation databases Cosmic; 1995608
Progenetix; CVCL_3112
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number34